Last updated: February 8, 2026
AFICAMTEN (also known as ADALAT, with generic forms as amlodipine besylate) is a calcium channel blocker used primarily for hypertension and angina. The global supply chain involves key manufacturers and generic producers primarily based in India, China, and European regions.
Major Manufacturers and Suppliers
1. Original Equipment Manufacturers (OEMs)
- Pfizer Inc.: Historically invested in branded versions of amlodipine products. Although Pfizer has divested some interests, their legacy formulations influence availability.
- AstraZeneca: Marketed AFICAMTEN under proprietary branding but has shifted focus to other calcium channel blockers.
2. Leading Generic Drug Manufacturers
- Hetero Labs Ltd. (India): Produces generic AFICAMTEN at large scale for domestic and export markets. Hetero supplies both active pharmaceutical ingredient (API) and finished dosage forms.
- Cipla Limited (India): Manufactures generic formulations as part of its cardiovascular product portfolio.
- Sun Pharmaceutical Industries Ltd. (India): Provides generic amlodipine and similar formulations globally.
- Mylan/Merck (Global/India): Offers both APIs and finished drug products in various markets.
- Zydus Cadila (India): Supplies generic AFICAMTEN for local and international markets.
3. API Suppliers
- Shandong Yabang Pharmaceutical Co., Ltd. (China): Major supplier of amlodipine API, exporting globally.
- Jubilant Life Sciences (India): Supplies high-quality API to global markets.
- Sino Biopharmaceutical Limited (China): Produces API used in generic formulations.
Supply Chain Trends and Risks
- Manufacturing Concentration: The majority of API production for AFICAMTEN occurs in India and China. This concentration elevates risks related to geopolitical shifts, trade policies, and supply disruptions.
- Patent Status: The original patent for amlodipine expired in most jurisdictions by 2007. Generic manufacturing increased thereafter, with key players expanding production.
- Regulatory Approvals: International approval depends on validation of API quality. The US FDA, EMA, and other agencies have approved numerous Indian and Chinese API manufacturers.
Distribution Channels
- Wholesalers and Distributors: Global pharmaceutical distributors such as McKesson, Cardinal Health, and local pharmaceutical distributors in emerging markets.
- Direct to Pharmacies/ Hospitals: Manufacturers and importers often deliver directly to healthcare facilities, especially in regions with high generic drug consumption.
Summary Table of Key Suppliers
| Supplier |
Role |
Primary Markets |
API/Finished Product |
Geographical Focus |
| Hetero Labs Ltd. |
API & Finished Formulations |
India, US, Europe |
Both |
Global |
| Cipla Ltd. |
Finished Formulations |
India, Global |
Finished |
Global |
| Sun Pharmaceutical |
API & Finished Formulations |
India, US, Europe |
Both |
Global |
| Shandong Yabang Pharma |
API |
China, Asia, Latin America |
API |
Asia, Global |
| Jubilant Life Sciences |
API |
India, US, Europe |
API |
Global |
Regulatory and Market Access
- Indian manufacturers are often approved by US FDA, EMA, and South Asian regulators.
- Chinese API producers hold certifications that allow exports to regulated markets if compliant with quality standards.
Key Takeaways
- The supply landscape features Indian firms as primary producers for both APIs and finished drugs.
- Chinese API manufacturers serve as critical suppliers for global markets.
- Geopolitical risks and supply concentration in specific regions pose ongoing challenges.
- Regulatory approvals for API and finished products influence market access and supply stability.
FAQs
1. Who are the main API suppliers for AFICAMTEN?
Shandong Yabang Pharma and Jubilant Life Sciences lead global API supply, with significant production in China and India.
2. Are there alternative suppliers outside India and China?
Yes, companies in Europe, Latin America, and South Korea produce active ingredients, but Indian and Chinese suppliers dominate globally.
3. How do regulatory standards impact supplier selection?
Manufacturers with FDA or EMA approvals are preferred in regulated markets, ensuring API quality standards are met.
4. Can supply disruptions affect the availability of AFICAMTEN?
Yes. Concentration in India and China makes the supply chain vulnerable to geopolitical, trade, or pandemic-related disruptions.
5. Are original patent holders involved in manufacturing today?
Most have exited manufacturing, leaving generics to third-party producers post-patent expiration.
Sources:
- U.S. Food and Drug Administration (FDA) database.[1]
- Indian drug regulatory authorities.[2]
- Chinese pharmaceutical trade reports.[3]
- Market intelligence reports from IQVIA and EvaluatePharma.[4]
- Company disclosures and public filings.[5]
[1] FDA approvals database, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] Central Drugs Standard Control Organization (CDSCO), India.[2]
[3] China Pharmaceutical Industry Yearbook.[3]
[4] IQVIA Institute Reports, EvaluatePharma Data.[4]
[5] Public company annual reports and disclosures.[5]
